The American Society of Clinical Oncology (ASCO) has recently named Molecular Profiling Driving Progress in Gastrointestinal Cancers as the Advance of the Year in Clinical Cancer Advances 2021. https://lnkd.in/gAjNrA4
Research has shown that targeting human epidermal growth factor receptor 2 (HER2) improves survival in gastric cancer and this is promising for patients with HER2-positive colorectal cancer. Therapy is currently approved that targets specific BRAF gene mutations in metastatic colorectal cancer. These recent advances are moving the treatment of gastrointestinal cancers closer to personalized medicine.
Visit us online @ guardanthealthamea.com
to find out more about Guardant360®, the global leader in liquid biopsy. If you have any queries, send us an email at email@example.com or contact us on WhatsApp: +65 8940 0360.
Guardant360®. Test. Take Action.